Issue 96

shoulders of the Shulgins

Standing on the Shoulders of the Shulgins

In July, Ann Shulgin passed away after a long battle with lung disease. Alongside late husband Alexander ‘Sasha’ Shulgin, Ann detailed the synthesis of 179 psychoactive compounds in TiHKAL and PiHKAL.

Alexander Shulgin is best known for creating phenethylamines, a class of compounds that includes psychedelic medicines mescaline and MDMA. Alexander Shulgin synthesised MDMA in 1976 and, upon noting its properties as an empathogen, introduced the compound to psychologists and therapists.

Until 1986, when the DEA placed MDMA on the Schedule 1 list of narcotics, the psychoactive compound was administered to thousands of patients in the first wave of psychedelic-assisted therapy. In support of their clinical application, Alexander wrote ‘Use them with respect as to the transformations they can achieve, and you have an extraordinary research tool.’

READ MORE

PSILOCYBIN THERAPY REDUCES HEAVY DRINKING DAYS BY 13%

Two high doses of psilocybin were administered in the double-blind clinical trial, in conjunction with psychotherapy.

Read More

FEDERALLY FUNDED RESEARCH TO BE MADE FREE TO ACCESS

The White House has updated policy guidance to make data from taxpayer-supported research freely available.

Read More

BUSINESS AND INVESTMENT

BraxiaField TripWesana and Red Light Holland report financial results.

Overstating the efficacy of psychedelic-assisted therapy.

The ethical development of psychedelic medicines.

MindMed doses first patient in Phase IIb trial.

Cybin doses first patient in Phase I/IIa trial.

Psychedelic-assisted therapy for racial trauma.

The use of ketamine as an antidepressant.

SCIENCE AND RESEARCH

Irish psychedelic research project gets government grant.

Psychedelic medicines to treat addiction disorders.

Young adults increase use of psychedelic medicines.

MAO inhibitors for treatment-resistant depression.

The Psychedelics as Medicine Report provides market insights from industry experts.

With over 60,000 downloads, the flagship publication contains proprietary data for regulators, researchers and investors to make informed decisions.

Previous partners include atai Life Sciences, COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact [email protected]

CONTACT FORM

REGULATION AND LEGISLATION

Opinion on psilocybin legislation in Colorado.

ARTICLES OF INTEREST

Sixty-eight per cent of Londoners have been struggling with poor mental health.

The mental health benefits of classic psychedelic medicines.